ProCE Banner Activity

Key Considerations for Using Biosimilars in IBD

Clinical Thought
The role of biosimilars in the setting of IBD is growing. Here’s my take on some of the key things you need to consider when using these agents.

Released: June 06, 2017

Expiration: June 05, 2018

No longer available for credit.

Share

Faculty

David T. Rubin

David T. Rubin, MD

Professor of Medicine
Chief,
 Section of Gastroenterology, Hepatology & Nutrition
University of Chicago Medicine
Chicago, Illinois

Provided by

Jointly provided by Postgraduate Institute for Medicine and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by an educational grant from

Pfizer, Inc.

Faculty Disclosure

Primary Author

David T. Rubin, MD

Professor of Medicine
Chief,
 Section of Gastroenterology, Hepatology & Nutrition
University of Chicago Medicine
Chicago, Illinois

David T. Rubin, MD, has disclosed that he has received consulting fees from AbbVie, AbGenomics, Celgene, Forward Pharma, Genentech/Roche, Janssen, Miraca Life Sciences, Pfizer, Samsung Bioepis, Sandoz, Shire, Takeda, and UCB and funds for research support from AbbVie, Genentech/Roche, Janssen, Prometheus, Shire, Takeda, and UCB.